Kerr Neilson is considered “Australia’s Warren Buffett” by many. Together with George Soros, he co-founded Platinum Asset Management. Platinum had an asset portfolio worth around $22 billion as of 2020. Johnson & Johnson, Facebook, Inc., and Alibaba Group Holding Limited are among the companies owned by Platinum Asset Management. Johnson & Johnson is a multinational pharmacy behemoth that has been at the forefront of vaccine development and delivery. The stock of Facebook, Inc. has increased by 50% in the last year. Workplace, Facebook’s latest business communications solution, has been gaining popularity. The app recently passed the 7 million paying user mark. Alibaba Group Holding Limited, also known as China’s Amazon, is another major holding of the fund manager. Alibaba recently announced the launch of a $5 billion underwritten registered public offering.
Insider Monkey gives a detailed overview of the best pharmaceutical stocks to buy according to billionaire Kerr Neilson. According to billionaire Kerr Neilson, Agios Pharmaceuticals, Inc. is the 10th best pharmaceutical stock to buy. In its Q1 FY2021 financial results, Agios announced $57.7 million in Research and Development. The company has announced plans to repurchase 7,121,658 outstanding shares from Bristol-Myers Squibb Company for $1.2 billion. Moderna, Inc. is a biotechnology and pharmaceutical company headquartered in the United States that specializes in the manufacture of messenger RNA-based vaccines. According to billionaire Kerr Neilson, MRNA is the ninth-best pharmaceutical stock to buy. In its Q1 FY2021 financial results, the company announced $1.9 billion in revenue, primarily due to the sale of the COVID-19 vaccine and a rise in international revenues. Gilead Sciences, Inc. is a biopharmaceutical company based in the United States that specializes in antiviral drug research and development for the treatment of sexually transmitted diseases. MYR GmbH, Immunomedics, and Forty-Seven were recently acquired by the corporation for $1.5 billion, $21 billion, and $4.9 billion, respectively. According to billionaire Kerr Neilson, Denali Therapeutics Inc. is the seventh-best pharmaceutical stock to buy. The FDA granted the company’s Hunter syndrome treatment Fast Track status in March (mucopolysaccharidosis type II) DNL310. The treatment is currently being tested in a Phase 1/2 trial. Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company specializing in the production of drugs to control the TGF-superfamily of proteins. Read more on this from the article 10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson.
